More than half of the diabetic type 2 has no proper control of the disease.

– in the Studio, with the endorsement of the Spanish society of Diabetes (thirst) and the Spanish society of physicians in primary care (SEMERGEN), they have participated so far close to 1,100 researchers and more than 3,000 patients

-diabetes affects 13.8 per cent of the adult population in Spain

Barcelona, November 2011- more than half of patients with type 2 diabetes does not have adequate control of the disease despite being diagnosed and treated pharmacologically. This is one of the main preliminary findings of the study DIABCONTROL, promoted by Almirall, to know the degree of control of type 2 diabetes, measured by hemoglobin glycosylated (HbA1c) in patients treated in primary care (PA), well as the control of cardiovascular risk factors.

DIABCONTROL study gives us an x-ray representative and valid for the status of these patients in Spain, because it is the first time that is measured by hemoglobin glicada with the same method, standardized internationally, in all centres ”, points out Dr. Antonio Pérez, Endocrinology and nutrition service(, Hospital de la Santa Creu i Sant Pau in Barcelona), and one of the coordinators of this project. The results show that patients who gained weight and those who have suffered some episode of hypoglycemia in the last year have worse glycemic control ”, adds.

For Dr. José Javier Mediavilla, from the Centre of Burgos Rural Health, Coordinator of the Group of Trabajo of Diabetes SEMERGEN and one of the coordinators of the study these data allow us to identify the problem as a whole and to know the degree of control, not only through glicada hemoglobin but also cardiovascular risk factors ”.

Main results of the study

The characteristics of the population studied in DIABCONTROL are representative of people with diabetes type 2 Spanish. The average age of the studied patients is 67-year-old obese most. The average time of evolution of type 2 diabetes is 9 years and more than 60% of patients treated with 2 or more drugs.

The main preliminary findings of the study include:

-more than 50% of patients have a poor glycemic control. These data confirm the findings of previous studies, but in this case the representativeness is greater, because it has been using the same method for the determination of hemoglobin glicada in all participants.

-patients who gained weight and those who have suffered some episode of hypoglycemia in the last year have worst control glycaemic.

-patients with worse glycemic control are those who have diabetes more evolved, valued by the time of evolution and the presence of complications, and those who receive a more complex hypoglycaemic therapy, especially treaties with insulin.

Methodology of the study

In the study, which so far has been valued at more than 3,000 patients, the inclusion of a total of 6.551 patients and to established diagnosis of diabetes mellitus type 2, is planned and the participation of approximately 2,000 researchers from medical consultations of the whole Spanish AP. DIABCONTROL has the endorsement of the Spanish society of Diabetes (thirst) and the Spanish society of physicians in primary care (SEMERGEN).

To know the percentage of patients with diabetes type 2 and treatment drug anti-hyperglycaemic with blood sugar control system is used a multi-análisis of quantitative determination of the percentage of hemoglobin (HbA1c) glicada in capillary blood (A1c Now +). The sample is obtained with a small puncture in the finger and the reading time is five minutes. Glicada hemoglobin measurement has become a differential approach and control indispensable for practitioners that cater to patients with diabetes, as it does not require the patient to be on fasting and reflects blood glucose from a long period.

Each researcher reviews the medical histories of patients with diabetes type 2 candidates to participate in the study who come to the medical consultation of AP for any reason (not necessarily for glycaemic control) and, once obtained informed consent and after verifying that it meets the selection criteriato study patient data will be collected.

Diabetes in Spain

Recent data of prevalence of diabetes in Spain, after the conclusive results of the study di@bet.es that were introduced in the last Congress of the SED, have revealed that diabetes affects 13.8% of the adult population, of which 6% desconocerían their situation (with preliminary data for October 2010 which pointed to a prevalence of 12% of the) (adult population with 4% of unknown diabetes). These data show that we are in line with the increase in the prevalence of diabetes worldwide.

Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. With headquarters in Barcelona (Spain), Almirall researches, develops, produces and sells drugs own r & d and licensing with the aim of improving the health and well-being of people.

The therapeutic areas in which concentrates its resources in research are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), gastrointestinal disorders, psoriasis and other
Forms dermatological.

Almirall drugs are currently present in over 70 countries. It has direct presence in Europe and Latin America through 12 subsidiaries.